Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance

Francesco Perna, Cesare Hassan, A Zullo, C Ricci, S Morini, D. Vaira

Risultato della ricerca: Contributo in rivistaArticolo in rivista

92 Citazioni (Scopus)

Abstract

First-line Helicobacter pylori therapy fails in more than 20% of patients. Quadruple therapy is the suggested second-line therapy, but bismuth salts are not anymore available worldwide. This study aimed to assess the efficacy of a levofloxacin-amoxycillin triple therapy as a second-line treatment, and the role of primary levofloxacin resistance.
Lingua originaleEnglish
pagine (da-a)1001-1005
Numero di pagine5
RivistaDIGESTIVE AND LIVER DISEASE
Volume39
DOI
Stato di pubblicazionePubblicato - 2007

Keywords

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Adult
  • Amoxicillin
  • Anti-Bacterial Agents
  • Breath Tests
  • Drug Resistance, Bacterial
  • Drug Therapy, Combination
  • Female
  • Helicobacter Infections
  • Humans
  • Male
  • Middle Aged
  • Ofloxacin
  • Prospective Studies
  • Proton Pump Inhibitors
  • Retreatment

Fingerprint Entra nei temi di ricerca di 'Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance'. Insieme formano una fingerprint unica.

Cita questo